Novartis AG (VTX:NOVN) Receives CHF 89.41 Average Target Price from Analysts
Novartis AG (VTX:NOVN) has been given a consensus recommendation of “Hold” by the fourteen research firms that are currently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, five have given a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is CHF 88.64.
NOVN has been the subject of a number of analyst reports. Credit Suisse Group set a €32.70 ($38.02) price objective on Software and gave the stock a “neutral” rating in a research note on Friday. Goldman Sachs Group initiated coverage on Enbridge in a research note on Thursday. They set a “neutral” rating for the company. Kepler Capital Markets set a €160.00 ($186.05) price objective on Pfeiffer Vacuum Technology and gave the stock a “buy” rating in a research note on Tuesday, May 21st. UBS Group restated a “neutral” rating on shares of CAIXABANK/ADR in a research note on Thursday. Finally, Morgan Stanley upped their price objective on Intact Financial from C$125.00 to C$128.00 in a research note on Thursday, May 30th.
Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.
Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.
See Also: How Do Mutual Funds Work?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.